Navigation Links
New opportunities for covalent drugs published by Avila scientists
Date:4/1/2011

WALTHAM, MA April 1, 2011 Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs" (www.nature.com/reviews/drugdisc, Vol. 10, April 2011, Singh, J.). This article discusses the broad opportunities for covalent drugs and how structural bioinformatics coupled with structure-based drug design can enable the design of highly selective covalent drugs with unique therapeutic properties for treating diseases.

"Many important and widely-used medicines work through a covalent mechanism of action," commented Juswinder Singh, PhD, Avila's Chief Scientific Officer and lead author on the publication. "Until recently, such covalent drugs were discovered by chance. However, today it is possible to design highly-specific covalent drugs by systematically applying rational drug design techniques and leveraging the vastly greater availability of structural information on disease targets. We anticipate the next few years will see an emergence of innovative covalent drugs that can solve problems that have been challenging for traditional medicinal chemistry approaches."

The Nature Reviews Drug Discovery article examines the prevalence of covalent drugs, safety considerations, mechanistic and pharmacological features, and approaches to design and optimization of targeted covalent inhibitors. Key points include:

  • Covalent drugs have made a major positive impact on human health, and there are dozens of covalent drugs on the market worldwide including broadly used medicines such as aspirin, clopidogrel (Plavix), lansoprazole (Prevacid) and esomeprazole (Nexium).

  • Despite the many successful covalent drugs, principles for the rational design of these molecules have only recently emerged. A description of progress in the design of targeted covalent drugs with a focus on the Avila strategy is discussed.

  • Several rationally designed, targeted covalent inhibitors have recently advanced in clinical development (neratinib, afatinib, PCI-32765 and the Avlia clinical candidate, AVL-292).

  • New publications have reported on targeted covalent inhibitors to diverse drug targets where each demonstrates high specificity of covalent bond formation to its respective target.

  • The pharmacological advantages of covalent drugs are discussed including the potential to address the problem of drug-resistance mutations that often arise in cancer and in infectious diseases.

Based on this review article, it is apparent that structural bioinformatics approaches, coupled with structure-based drug design, may enable the engineering of highly selective covalent drugs and a resurgence of interest in this important class of therapeutics.


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Related biology news :

1. IEEE-USA workshop to explore the challenges and opportunities of electric vehicle technology
2. New oyster farming technique increases productivity, offers entrepreneurial opportunities
3. IBIA Statement Regarding the Release of the National Research Council Report - Biometric Recognition: Challenges and Opportunities
4. Behind the secrets of silk lie high-tech opportunities
5. New book describes career opportunities in clinical research and how to qualify for them
6. Conference to discuss sensing technology developments and opportunities
7. Male antelopes trick females into extra sex opportunities
8. George Daley to discuss challenges and opportunities facing stem cell scientists
9. Synthetic biology offers new opportunities for interdisciplinary collaboration
10. NIGMS invests in scientific Grand Opportunities with Recovery Act funds
11. Frost & Sullivan Looks at Biometrics Advancement in Civil Security: Exploring Opportunities for Today and Beyond
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology: